Effective as of June 1, 2026, the Board of Directors (the “Board”) of Alnylam Pharmaceuticals, Inc. (the “Company”), following the recommendation of its Nominating and Corporate Governance Committee, expanded the size of the Company’s Board from ten to eleven and elected Benjamin F. Cravatt, Ph.D. to fill the newly created vacancy.
Key facts
Extracted from this filing and checked against the source text.
Executive changeSEC 8-K Item 5.02confidence 0.95
Benjamin F. Cravatt was elected as Director at ALNYLAM PHARMACEUTICALS, INC..
Action
elected
Role
Director
Exact text from the filing
Effective as of June 1, 2026, the Board of Directors (the “Board”) of Alnylam Pharmaceuticals, Inc. (the “Company”), following the recommendation of its Nominating and Corporate Governance Committee, expanded the size of the Company’s Board from ten to eleven and elected Benjamin F. Cravatt, Ph.D. to fill the newly created vacancy.
ALNYLAM PHARMACEUTICALS, INC. shareholders approved Non-binding advisory vote on compensation of named executive officers.
Proposal
say on pay
Outcome
passed
Exact text from the filing
2. The Company’s stockholders approved, in a non-binding advisory vote, the compensation of the Company’s named executive officers. The voting results were as follows: Votes For Votes Against Abstentions Broker Non-Votes 111,772,389 8,552,534 41,495 5,450,286
ALNYLAM PHARMACEUTICALS, INC. shareholders approved Ratification of PricewaterhouseCoopers LLP as independent auditors at the 2026-12-31 meeting.
Proposal
auditor ratification
Outcome
passed
Meeting
2026-12-31
Exact text from the filing
3. The Company’s stockholders ratified the appointment by the Company’s Board of Directors of PricewaterhouseCoopers LLP as the Company’s independent auditors for the fiscal year ending December 31, 2026. The voting results were as follows: Votes For Votes Against Abstentions Broker Non-Votes 119,847,735 5,937,274 31,695 0
ALNYLAM PHARMACEUTICALS, INC. shareholders approved Re-election of three Class I directors.
Proposal
director election
Outcome
passed
Exact text from the filing
1. The Company’s stockholders re-elected the three persons listed below as Class I directors, each to serve until the Company’s 2029 annual meeting of stockholders or until his or her successor is duly elected and qualified. The voting results were as follows: Votes For Votes Against Abstentions Broker Non-Votes Stuart A. Arbuckle 115,269,659 5,068,463 28,296 5,450,286 Yvonne L. Greenstreet, M.D. 119,787,307 513,049 66,062 5,450,286 Elliott Sigal, M.D., Ph.D. 107,495,421 12,844,836 26,161 5,450,286
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.